Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

NEWS FEEDS

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

November 19, 2015

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and appropriate treatments and encourage future innovation? As stakeholders meet in Washington, DC, on November 20 at the HHS Pharmaceutical Forum, we hope that they’ll consider a few of the ideas below, many of which we have discussed in greater detail in peer-reviewed research. This is not a comprehensive list, but rather a starting point for a constructive conversation.

Considering Risk-Sharing Agreements.

Under risk-sharing agreements (RSAs), health care payers and biopharmaceutical manufacturers agree to link coverage and reimbursement levels to a drug’s effectiveness and/or how frequently it is utilized. According to a recent study, there are benefits to these arrangements. Manufacturers can use RSAs to differentiate and demonstrate the effectiveness of their product versus their competitors, which can assist payers in making formulary decisions. Payers can utilize RSAs to gain experience with a product, reducing uncertainty regarding clinical value, performance and financial impact. Yet existing barriers, such as the effort and expense involved in patient monitoring, make it difficult to design and implement RSAs in the current U.S. health care environment.

Moving From “How Much” to “How Well” We Spend.

One approach toward reducing health costs currently being tested in the Medicare program and by some employers is value-based insurance design (V-BID). V-BID shifts the focus from “how much” to “how well” we spend health care dollars. V-BID is driven by the concept of clinical nuance, which recognizes that medical services differ in the benefit they provide, as well as the benefit each individual patient experiences from a particular service. By incentivizing consumers to utilize the treatments that are most beneficial to them, this could shift spending to higher value care.

Recognizing Individual Patient Differences Via Copays.

Each patient may respond differently to a particular treatment, meaning that a biopharmaceutical listed on the first tier of a formulary may not work well for everyone. The individual who does not respond well to that first biopharmaceutical might need to try one or more treatment options until finding one that works best, which might be on a higher, or more expensive tier of the formulary. Should that person be required to pay more for a medicine—whether it’s brand or generic—simply because his or her biological response is different?

Recognizing the Full Value of Treatments.

There is no one “value assessment framework” that can accurately determine all aspects of the value of a treatment for an individual patient, society and continued innovation. With the Institute for Clinical and Economic Review Value Assessment Framework, for example, there is a lack of model transparency, challenges with how the budget impact is calculated, and the need to realize the effects of some treatments over a longer time horizon, among other concerns. With the American Society of Clinical Oncology’s (ASCO) Conceptual Framework to Assess the Value of Cancer Treatment Options, it will be important to broaden and sharpen many of the framework’s components and ensure that it is not misused to limit access to life-extending cancer treatment regimens. It also is important to be mindful of the flaws in current assessments and ensure that they are not misused.

Understanding and Addressing the Gaps in Quality Measurement.

Quality measures play a critical role in the implementation of accountable care organizations (ACOs), as physician payments will be based on how they measure up against quality metrics. It’s important to understand how these delivery and payment structures save money, as well as whether they result in improved patient health.

A first step is to examine where gaps exist in quality measurements for prevalent and costly health conditions such as breast cancer, HIV, diabetes and stroke, and to evaluate whether we are incenting the most appropriate and effective treatments for patients with these illnesses. We need to continue strengthening our understanding of how new payment models may be impacting individual patient care and health outcomes, as well as how biopharmaceuticals fit into these models.

Collaborating on Data.

Thanks to innovation in the technology sector, we are now starting to see the benefits of a revolution in health care data and, with it, the potential to make health care payment and delivery even more effective and cost-efficient. Through electronic health records, claims data and even wearable devices, we are able to gather insightful, real-world evidence about how health care is being delivered, the quality of that care, and how biopharmaceutical treatments are performing in patients in everyday settings. This is even an area in which segments of the biopharmaceutical and insurance sectors have been able to collaborate to conduct real-world studies designed to determine how to most effectively and economically treat disease. How payers will utilize this evidence in making coverage decisions is still a work in progress, however, as new methods are being developed to ensure the quality of the data and how the research study is conducted, as well as how the evidence is evaluated.

Similarly, broader access to research-quality data taxpayer-funded databases could help researchers tackle a host of health care questions that cannot be addressed through other information sources. Although the Centers for Medicare and Medicaid Services recently allowed biopharmaceutical companies to access certain federal databases, access to state all-payer claims databases remains limited.

Enabling More Open Conversations Between Payers and the Biopharmaceutical Industry.

Section 114 of the Food and Drug Administration Modernization Act (FDAMA) of 1997 established a special mechanism for health care economic information that biopharmaceutical companies can share with payers. According to research on FDAMA 114 funded by NPC, “the language of Section 114 is sufficiently vague … leaving legal, regulatory, health economics, and other teams within drug companies to interpret the statute and gauge the company’s risk tolerance. The seemingly limited use of Section 114 to date may reflect companies’ uncertainty about its scope… In practice, it is hard to know exactly what the law allows given the imprecision of the statute and the lack of guidance about its scope.”

The uncertainty around Section 114 can present a barrier to the exchange of important information that payers need to make formulary decisions.

Now it’s time to roll up our sleeves and begin the conversation.

Interested in learning more about these and other important health policy issues? Stay up to date on these topics by visiting NPC's website, subscribing to our email alerts, and following us on Twitter at @npcnow. Check out NPC’s blog, Evidently Today, to view the previous posts in this series.

[Note: Previous posts in this series focused on considering all health costs; strengthening an innovative environment; and balancing quality improvement with patient access as we shift to value-based care.]

Newsletter Volume

E.V.I.dently January 2016

MessageThe Importance of Evidence, Value, Access and Innovation in 2016In his annual health care outlook, NPC President Dan Leonard explains why...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Newsletter Volume

E.V.I.dently November 2015

MessageCan We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?Has biopharmaceutical innovation brought value and made a...
Blog Post

The Shift to Value-Based Care: Balancing Quality Improvement with Patient Access

Over the last few years, there has been a significant shift throughout our health care system to move to a delivery and payment model known as value-...
Press Release

Specialty Medications: Shifting the Focus From “How Much” We Spend to “How Well” We Spend

Washington, DC, June 9, 2014—As health care decision-makers grapple with how to ensure access to specialty medications, the University of Michigan...
Press Release

National Pharmaceutical Council Welcomes Amgen as Its Newest Member

Washington, D.C. (January 16, 2013)—The National Pharmaceutical Council (NPC) today welcomed biotechnology pioneer Amgen as its newest member. Joshua...
Press Release

Pharmaceuticals Play Key Role in Achieving ACO Quality, Cost Goals

WASHINGTON, DC, July 18, 2012–As health care providers set up accountable care organizations (ACOs) and other value-based care programs,...
Press Release

National Pharmaceutical Council Expands Policy and Research Staff

WASHINGTON, DC (January 4, 2012) -- The National Pharmaceutical Council (NPC) announced the hiring of Daryl Pritchard, PhD, as the Director of...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
Commentary and Testimony Page

Health Care Reform and Pharmaceutical Innovation

Although the Patient Protection and Affordable Care Act of 2010 (PPACA) is expected to have broad societal benefits, moving forward, it will be...
YouTube Videos

Accountable Care Measures for High-Cost Specialty Care and Innovative Treatment

Tom Valuck, MD, MHSA, JD, partner, Discern Health, is a co-author of the white paper "Accountable Care Measures for High-Cost Specialty Care and...
YouTube Videos

Patients, Research and Access to Health Care

Myrl Weinberg, FASAE, CAE, president of the National Health Council, says that it's important to for individuals, especially those with chronic...
YouTube Videos

CER and Its Impact on Pharma Innovation

Dr. Darius Lakdawalla, director of research at the Schaeffer Center for Health Policy and Economics at the University of Southern California,...
Blog Post

The Shift to Value-Based Care: Balancing Quality Improvement with Patient Access

Over the last few years, there has been a significant shift throughout our health care system to move to a delivery and payment model known as value-...
Blog Post

Pharmaceutical Innovation’s Role in the Panorama of Health System Improvement and Population Health

When he announced the launch of the White House Precision Medicine Initiative, President Obama said, “If we have the opportunity to prevent hurt and...
Blog Post

At the HHS Pharmaceutical Forum, We Need to Consider All Health Care Costs

On November 20, stakeholders will come together for a day-long event—“HHS Pharmaceutical Forum: Innovation, Access, Affordability and Better Health”—...
Blog Post

Value Is in the Eye of the Beholder? NPC Takes Closer Look at ICER Framework

In recent months, a number of health organizations have developed “value assessment frameworks,” which are designed to inform coverage and treatment...

Designing Successful Bundled Payment Initiatives

The National Pharmaceutical Council led a study that identified three principles intended to...

Private Sector Risk-Sharing Agreements in the US: Trends, Barriers and Prospects

A peer-reviewed study found that there are limited risk-sharing agreements (RSAs) between health...
  •  
  • 1 of 9
  • >